Eli Lilly’s $8 billion acquisition of Loxo Oncology looks like it could pay off, with new data for RET inhibitor selpercatinib setting up a filing before the end of the year. The results of the ...
AUSTIN, Texas, Feb. 20, 2025 /PRNewswire/ -- Loxo, a talent intelligence platform and recruiting software company, today announced its closing of a growth investment led by Tritium Partners ...